- Home
- NEPH vs MTVA Comparison
NEPH vs MTVA Comparison
Compare NEPH & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEPH
- MTVA
- Stock Information
- Founded
- NEPH 1997
- MTVA 2014
- Country
- NEPH United States
- MTVA United States
- Employees
- NEPH N/A
- MTVA N/A
- Industry
- NEPH Medical/Dental Instruments
- MTVA
- Sector
- NEPH Health Care
- MTVA
- Exchange
- NEPH Nasdaq
- MTVA NYSE
- Market Cap
- NEPH 16.8M
- MTVA 13.6M
- IPO Year
- NEPH 2004
- MTVA N/A
- Fundamental
- Price
- NEPH $2.03
- MTVA $1.54
- Analyst Decision
- NEPH Buy
- MTVA Strong Buy
- Analyst Count
- NEPH 1
- MTVA 1
- Target Price
- NEPH $5.00
- MTVA $12.00
- AVG Volume (30 Days)
- NEPH 12.2K
- MTVA 21.0K
- Earning Date
- NEPH 05-08-2025
- MTVA 05-08-2025
- Dividend Yield
- NEPH N/A
- MTVA N/A
- EPS Growth
- NEPH N/A
- MTVA N/A
- EPS
- NEPH 0.01
- MTVA N/A
- Revenue
- NEPH $14,162,000.00
- MTVA N/A
- Revenue This Year
- NEPH $9.23
- MTVA N/A
- Revenue Next Year
- NEPH $12.99
- MTVA N/A
- P/E Ratio
- NEPH $290.01
- MTVA N/A
- Revenue Growth
- NEPH N/A
- MTVA N/A
- 52 Week Low
- NEPH $1.36
- MTVA $1.29
- 52 Week High
- NEPH $2.55
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- NEPH 76.08
- MTVA N/A
- Support Level
- NEPH $1.55
- MTVA N/A
- Resistance Level
- NEPH $1.62
- MTVA N/A
- Average True Range (ATR)
- NEPH 0.10
- MTVA 0.00
- MACD
- NEPH 0.04
- MTVA 0.00
- Stochastic Oscillator
- NEPH 98.18
- MTVA 0.00
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.